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Rationale: Tissue Factor (TF) is a transmembrane glycoprotein that canonically functions as the 
initiator of the coagulation cascade. Increased levels of TF have been associated with 
inflammatory airway diseases. Since lipopolysaccharide (LPS) is known to elicit and 
inflammatory response in airway epithelium, we hypothesized that airway epithelial cells 
release TF when exposed to LPS. Since TF aids in local wound healing, we also hypothesized that 
inhibition of TF would decrease NHBE growth. The specific aim of this work was to evaluate the 
effects of LPS exposure on TF production and release from airway epithelia and determine the 
signaling pathways involved.  A secondary aim was to evaluate the effects of TF inhibition on 
NHBE growth. 
Methods: Normal human bronchial epithelial cells were grown in submerged cell culture and 
exposed to LPS as well as several intracellular signaling pathway agonist and inhibitors.  
Measurements: Tissue Factor mRNA and protein were measured in culture media and cell 
lysate by reverse-transcriptase polymerize chain reaction and enzyme-linked immunosorbent 
assay, respectively.  Signaling pathways were evaluated using selective agonists and inhibitors. 
Main results: TF protein levels increased nearly two-fold in cell media after exposure to LPS (p < 
0.01). This did not occur in the presence of an MEK/ERK inhibitor (PD98059) or a SMAD 
inhibitor (SB431542). TF protein levels also increased nearly ten-fold in the presence of TGF-
beta (p < 0.05). mRNA of TF and TGF-beta was not altered by LPS or TGF-beta exposure. NHBE 
grown in the presence of Tissue Factor Pathway Inhibitor grew significantly slower than those 
grown in standard media (P < 0.05).  
Conclusions: NHBE release TF when exposed to LPS. This phenomenon is post-translational and 
may be mediated by an autocrine mechanism involving MEK/ERK signaling that increases TGF-
beta which then leads to the release of TF. Our data suggest that this airway epithelium release 
of TF serves as a local repair function.  
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Chapter 1: Introduction 
 
 
1.1 Background 
 
Tissue Factor (TF) is a 47 kDa transmembrane glycoprotein that structurally resembles a 
cytokine receptor and canonically functions as an initiator of the coagulation cascade1-
5.Vascular endothelium, fibroblasts, smooth muscle cells, and epithelial cells constitutively 
express TF1-5. When exposed to Factor VII (FVII), which is present in circulating blood, TF 
activates FVII (FVIIa) binds with FVIIa and forms a complex that triggers the Factor X (FX) 
pathway of coagulation1-5. This leads to self-amplified activation of FVII, thrombin production, 
and eventually clot formation and tissue growth (Image 1). Lipopolysaccharide (LPS) can also 
induce expression of TF in monocytes and vascular endothelium via AP-1 and NF-kB which also 
lead to thrombin/fibrin clot formation in blood4. Both of these indicate that TF activates in 
response to blood presence or local inflammation1-5. An endogenous inhibitor of TF called 
Tissue Factor Pathway Inhibitor (TFPI) balances TF activity in vivo by interfering with TF/FVIIa 
complexes as well as FX6, 7. 
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1.2 TF and Disease 
 
Most translational research involving TF has focused on its role in coagulopathies1, 2, 4, 5. 
However, in the past three decades TF has been identified in blood and other fluids. Serum TF 
expression increases in physiologic disturbances including disseminated intravascular 
coagulation8, hemorrhage5, and disorders that increase capillary permeability such as sepsis 
and systemic inflammatory disorders9, 10. TF has also been shown to promote cell proliferation 
and migration3. 
Increased levels of systemic and local tissue TF have also been associated with pulmonary 
diseases including pulmonary fibrosis11-13 and acute lung injury10, 14.  Since all systemic blood 
flows through the vasculature in the areas affected by these disorders and these disorders are 
associated with capillary membrane leakage, local increases in TF caused by these disorders 
could stem from increased circulating TF levels leaking into the airways.   
 
1.2.1   TF and Inflammatory Airway Disease 
 
In 2009, Brims et al reported that subjects with severe asthma had higher levels of TF in 
their sputum than subjects with moderate asthma or control subjects, even while undergoing 
treatment15. Increased levels of TF have been reported in airway fluids from subjects with 
inflammatory airway diseases including pneumonia16, 17, bronchopulmonary dysplasia18, and 
asthma15, 19. This could be related to tissue remodeling and wound healing commonly 
associated with these disorders.  These findings were initially attributed to vascular leakage into 
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the airway lumen, however Park et al reported in 2012 that cultured normal human bronchial 
epithelium (NHBE) produced and released TF bound to exosomes in response to cyclic stress20. 
Since cyclic stress stretches and can rupture cell membranes, and TF is known to aid in wound 
healing and hemostasis5, 21, 22, it is probable that the release of TF in this setting would function 
to aid in tissue repair from potential stretch damage. 
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Image 1: Cartoon of TF Activity.  
 
1. Upon exposure to serum, extravascular TF forms a complex with activated Factor VII (FVIIa). 
2. Activated Factor X (FXa) interacts with Factor V (FV) to activate Factor VII (FVII) to Factor VIIa 
(FVIIa). 3. FXa forms a complex with activated FV, generating thrombin. 4. This thrombin 
perpetuates activation of FV and FVII, leading to 5. Platelet activation and continued 
coagulation.  (modified from Eilertsen 20041) 
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1.3 Tissue Factor Pathway Inhibitor 
 
TFPI is an endogenous compound that canonically inhibits the activity of TF6, 7.  It binds with 
activated FX and reversibly inhibits its ability to promote thrombin/fibrin formation6, 7.  
Subsequently, TFPI binds with TF/FVII complexes and prevents their ability to further activate 
the FX pathway (Image 2).  Vascular endothelium synthesizes most of this ~40 kDa modular 
protein6.  Over the past two decades, TFPI has been shown to be synthesized in small amounts 
by most human cell types. The exceptions to this are hepatocytes, erythrocytes, neutrophils, 
and lymphocytes6, 7.   
Although the specific mechanism of TFPI activation remains unknown, several factors are 
known to increase TFPI expression.  Cells that constitutively express TFPI increase synthesis in 
response to plasma exposure6, 7, shear stress6, 23, and thrombin presence24.  Inflammatory 
stimulation, such as that by LPS, TNF-a, and IL-1, has been shown to decrease TFPI expression25. 
Decreased levels of TFPI have been associated with acute lung injury26, 27, pulmonary fibrosis11, 
and acute respiratory distress syndrome14.  
Although cellular expression of TFPI increases with TF expression, TFPI does not increase 
above the basal levels of TF which makes it incapable of blocking TF in the setting of acute 
inflammation14, 28, 29.  This suggests that TF and TFPI normally exist in a balanced state but that 
TFPI cannot balance abnormally increased amounts of TF.  This observation has led to interest 
in therapeutic applications of exogenous TFPI17, 27, 30-32. 
- 6 - 
 
Image 2: Cartoon of TFPI Activity. 
 
TFPI inhibits both FXa and TF/FVIIA complexes.  Modified from Bajaj 20016. 
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1.4 Airway Cell Models 
 
 Airway cell culture can be used as models of healthy and diseased airway.  Human airway 
cells are commercially available and a variety of models have been developed.  Two types of 
these models were used for the work reported here – differentiated and undifferentiated cell 
culture. Each of these models has specific benefits. Below is a brief background on these 
models. 
 
1.4.1   Undifferentiated Airway Cell Culture 
 
When grown under submerged conditions, NHBE cells stay in an undifferentiated, basal-
type form similar to that seen during growth and wound repair which makes this model helpful 
when studying these states33. This model of cell culture is one of the simplest; the cells are 
grown on a surface such as a flask or culture well and media is layered on top of them (Image 
3a). Submerged cell culture techniques have been used for decades and are well established in 
airways cells.  Being submerged in cell media also protects these cells from the environmental 
contamination. Due to the robust nature of this culture model and the widely available 
established techniques, it is convenient to use34, 35.    
 
 
 
 
- 8 - 
 
1.4.2  Differentiated Airway Cell Culture 
 
The development of semi-permeable membranes conducive to cell culture has enabled the 
culture of polarized and differentiated cells at an air-liquid interface (ALI) in which the media is 
able to feed cells from below a membrane on which they are grown (Image 3b-c). This is 
beneficial to airway researchers since NHBE in vivo are exposed to air apically. These ALI 
conditions allow cells to fully differentiate from their submerged precursor form to polar 
pseudostratified ciliated columnar epithelium. The final product is a functioning piece of airway 
epithelium. 
These models allow investigators to evaluate the response to stimuli applied to the apical or 
basolateral sides of airway cells which are representative of the airway lumen and parenchyma, 
respectively.  Because these cells are exposed directly to the atmosphere, this model is more 
vulnerable to contamination.  Also, the techniques required to maintain cell growth are precise 
and less forgiving.  Finally, this model takes approximately a month to reach differentiation.  
These features contribute to the complex nature of this differentiated airway cell culture34, 35. 
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Image 3: Depictions of cell culture models. 
 
(A) In the classic model of submerged cell culture, cells are grown on the bottom surface of a 
cell culture flask and remain submerged under cell media. When growing cells in an air-liquid 
interface, cells are grown atop a semipermeable membrane that allows nutrients from media to 
pass through and feed the cells.  (B) Initially, the cells maintain submerged underneath media 
but eventually the apical media is removed and (C) cells are able to fully differentiate. Modified 
from Stem Cell Technologies (www.stemcell.com). 
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1.5 LPS-induced Airway Inflammation Model 
 
LPS is a well-described initiator of inflammatory responses throughout the body35-37. 
Although classically used as a model for bacterial infection since Gram-negative bacteria 
express LPS on their cell membrane, LPS is now used as an airway inflammation model due to 
its consistent activation of toll-like receptor 4 (TLR-4)35-37. LPS binds to TLR-4 and activates 
intracellular signaling pathways, including mitogen-activated protein kinase/extracellular signal-
regulated kinases (MEK/ERK) and IkB kinases (IKK) which lead to AP-1 and NFkB activation, 
respectively (Image 4)35-37.   
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Image 4: Cartoon depiction of signaling pathways affected by LPS activation of TLR-4.  
 
Pathways evaluated in these experiments, MEK/ERK and IKK, are circled in red. Modified from 
public domain. 
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1.6 Specific Aims 
 
Since many of the diseases associated with TF in airway fluid have been inflammatory 
airway diseases, I hypothesized that an inflammatory insult may induce NHBE release of TF 
similar to that seen after cyclic stress of NHBE20. Specifically, I hypothesized that LPS exposure 
would induce TF release. The specific aims of this work were to identify whether NHBE produce 
and release TF in response to LPS stimulation and to elucidate the mechanism(s) by which that 
occurs. A secondary aim was to evaluate functions of airway epithelial TF; specifically, although 
I initially hypothesized that TF was pro-inflammatory and would promote the production of 
inflammatory mediators, following the studies to address Specific Aim 1 it appeared that TF was 
more likely involved in cell growth and repair, and so I evaluated the effects of TF inhibition on 
the rate of cell growth.    
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Chapter 2: Methods 
 
 
2.1 Submerged Airway Epithelial Cell Culture 
 
Primary NHBE cells used for all experiments described were healthy, non-smoker donor 
cells purchased from Lonza (Basel, Switzerland). Cell media used was Bronchial Epithelial 
Growth Media with the SingleQuot Supplement Kit (Lonza) that included: hydrocortisone, 
gentamicin, retinoic acid, bovine pituitary extract, recombinant human insulin, transferrin, 
triiodothyronine, epinephrine, and human epidermal growth factor. Cells were grown under 
submerged conditions until confluent in 75 cm2 cell culture flasks (Image 3a). After confluence, 
which takes 5-6 days, the cells were exposed removed from the flask by trypsin exposure for 
five minutes after which trypsin neutralizing solution (TNS) was added. These cells were then 
counted by a digital cell counter (Bio-Rad Laboratories Inc., Hercules, CA, USA) with viability 
determined by trypan blue staining and then passaged into 15.6 mm cell culture wells (Corning, 
New York, USA) at 20,000 cells per well under 500 uL of media per well which lead to 
approximately 10% confluence.  The cells were then grown again until confluent (5-7 days). Cell 
media was changed every 48 hours. 
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2.1.1  Evaluation of Confluence/Cell Growth 
 
Immediately after each media change, cells were viewed via light microscopy and 
confluence was noted as percentage of the culture well covered by cells. For all experiments, 
confluence was considered to be the point at which >80% of culture well was covered by cells. 
Only culture wells that grew at the same pace were included in comparative experiments.  
When comparing different levels of confluence, percentage estimates were verified using 
ImageJ to count cells in photographs taken during light microscopy (https://imagej.nih.gov/ij). 
 
 
2.2 Air-Liquid Interface Airway Epithelial Cell Culture 
 
Primary NHBE cells were grown in ALI culture until fully differentiated as pseudostratified 
ciliated columnar epithelial cells. Cells were grown under submerged conditions as described 
above until confluent in a 75 cm2 cell culture flask and then passaged into 6.5 mm transwell 
culture wells (Corning) at 200,000 cells per well under 100 uL of media and above 500 uL of 
media per well (Image 3b). Cell media was homemade and contained the same supplements 
described above (Section 2.1) but in 10-fold higher quantities to sustain the higher number of 
cells grown.  36 hours after confluence, apical media was removed.  Ciliary beat was observed 
under light microscopy after 10 days to verify differentiation (Image 3c).   
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2.3 Biomarker Analysis 
 
2.3.1   Enzyme-Linked Immunosorbent Assay 
 
TF and TGF-beta protein levels were quantified using commercially available enzyme-linked 
immunosorbent assays (ELISA) from R&D Systems (R&D Systems, Inc., Minneapolis, MN, USA). 
Assays were run according to the manufacturer’s specifications. TF protein was measured in 
undiluted cell media. Standard curves were initially run in parallel using the manufacturer-
recommended reagent diluent and cell media as a diluent to rule out artifact or a matrix effect 
caused by the presence of cell media in samples; no difference was noted and subsequent 
standard curves were run using the manufacturer-recommended reagent diluent. TGF-beta 
protein was measured in cell lysate after lysis with RIPA buffer. During initial assay optimization 
the manufacturer-recommended reagent diluent was compared to RIPA buffer to rule out 
potential artifact in samples. No difference was noted between diluents and manufacturer-
recommended reagent diluent was used for subsequent standard curves. 
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2.3.2   Polymerase Chain Reaction 
 
After LPS exposure, cells were washed three times with PBS and total RNA was extracted 
using the Aurum™ Total RNA Mini Kit (Bio-Rad Laboratories Inc.). Total RNA was used to 
synthesize the first-strand cDNA (Script TM cDNA synthesis kit; Quanta BioSciences, Inc., 
Gaithersburg, MD, USA). Reverse Transcription Polymerase Chain Reaction (PCR) was 
performed on the C1000TM thermal cycler equipped with CFX96TM real-time PCR system (Bio-
Rad Laboratories Inc.). Total RNA was determined in samples via use of a Nanodrop 200c 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA) after which samples were 
normalized to RNA concentration. For the relative quantification of TF mRNA expression, the 
expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as a housekeeping 
control. Perfecta SYBR Green (Quanta BioSciences, Inc.) was used as a DNA intercalator dye to 
monitor amplified DNA quantification and real-time quantitative PCR curves were analyzed by 
CFX Manager software (Bio-Rad Laboratories Inc.) to obtain threshold cycle values for each 
sample. TF primers used were forward sequence 5’-ACAGAGTGTGACCTCACCGACGA-3’ and 
reverse sequence 5’-CCTGCAGGGTAGGAGAAGACCC-3’. 
 
2.3.3.  Colorimetric Assay 
 
Lactate dehydrogenase (LDH) was measured using the Pierce LDH Cytotoxicity Assay which 
is a commercially available colorimetric assay (Pierce Biotechnology, Rockford, Illinois, USA). 
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Assays were run according to manufacturer’s specifications. LDH was measured in undiluted 
cell media. 
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2.4 Evaluation of Signaling Pathways 
 
Cells were exposed to 10 ug/mL LPS in the basolateral media for several different time 
courses; the time of exposure at which the largest protein signal was observed was 24 hours 
(which has been previously reported), so, we subsequently used this time point for all LPS 
exposures.  We have previously reported that 10 ug/mL LPS will activate MEK/ERK without 
causing cell death and used this model for our reported experiments36.  
Specific pathways by which LPS induces TF release were evaluated via selective antagonist 
exposures in separate experiments. For these experiments, the selective antagonist was added 
to cell media along with LPS or vehicle for the duration of the exposure. Excipients for each 
antagonist were added to control groups to prevent artifact. PD98059 was used to evaluate 
MEK/ERK signaling, PS1145 was used to evaluate IKK signaling, and SB431542 was used to 
evaluate SMAD signaling (R&D Systems, Inc.).    
 
 
2.5 TF Inhibition 
 
TF has an endogenous specific inhibitor called TFPI (Image 2).  This commercially available 
compound functions in vivo to balance TF6, 7, 18, 28, 29.  To evaluate the function of TF in cell 
growth, we added TFPI (R&D Systems, Inc) to cell media during each media change. Since NHBE 
grown in submerged cell culture are precursors to differentiated NHBE that canonically function 
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during tissue development and wound healing, we used this culture model (Image 3a) for these 
experiments.   
 
 
2.6 Statistical Analysis 
 
Sample sizes for each group were determined to be appropriate to achieve a level of 
significance of 0.05 and a power of 0.80 (G*Power Software, Universitat Kiel, Germany). 
Statistical analyses were performed using SigmaStat (Systat Software, Inc., San Jose, CA). 
Student’s unpaired, two-tailed t-test was used to evaluate protein and mRNA levels comparing 
control groups and exposure groups. Wilcoxon rank-sum test was used for non-Gaussian 
distributed data as determined by the Shapiro-Wilk test. For multiple group exposures, analysis 
of variance (ANOVA) or ANOVA on ranks was used. A Bonferroni correction was used to account 
for multiplicity. A p-value of less than 0.05 was considered statistically significant.  
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Chapter 3: Release of TF from NHBE after LPS Exposure 
 
3.1 Rationale and Hypothesis 
 
 We sought to determine whether NHBE produce and release TF in response to LPS 
stimulation and to elucidate the mechanism by which that occurs. We used airway cell culture 
models for all experiments since these allow for evaluation of local airway epithelial biomarker 
production.  We hypothesized that cultured airway epithelial cells produce and release TF and 
that this production and release is increased by LPS exposure. Specifically, I hypothesized that 
these increases were mediated by MEK/ERK and SMAD signaling mediated by TGF-beta (Image 
5).  
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Image 5: Schematic diagram of experiments. 
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3.2 Results 
 
3.2.1 Differentiated NHBE does not release TF after LPS exposure 
 
 Primary NHBE cells from three separate donors were grown in ALI culture conditions 
until fully differentiated as pseudostratified ciliated columnar epithelial cells. TF protein levels 
were measured via ELISA in apical and basolateral media. TF protein was not statistically 
different between control or LPS groups at any time point (Figure 1). Since LPS is known to 
induce an increase in CXCL8 release from NHBE, we evaluated CXCL8 levels in media as a 
positive control for LPS function.  CXCL8 was increased in the LPS groups compared to the 
control groups (p < 0.01 Figure 1). These results indicate that differentiated pseudostratified 
ciliated columnar epithelial cells do not release TF in response to LPS exposure. 
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Figure 1: Differentiated NHBE does not release TF when exposed to LPS. 
 
 
Cells grown in ALI were exposed to 10 ug/mL LPS in the basolateral media for 24 hours. TF was 
measured via ELISA in (A) apical and (B) basolateral media.  No statistically significant change 
was noted between control and LPS groups. Results were normalized to reflect TF change vs. 
control. (C) LPS exposure significantly increased released CXCL8 protein (p < 0.05 indicated by 
asterisk). All results are reported as means plus and minus standard error of the mean. 
 
A. 
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B. 
 
 
 
 
 
 
C. 
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3.2.2 TF protein release from undifferentiated NHBE increases after LPS exposure 
  
Since differentiated pseudostratified ciliated columnar epithelium did not respond to LPS 
exposure by releasing TF, we evaluated TF release from a submerged cell culture model. The 
undifferentiated precursor airway cells that develop in submerged conditions are 
representative of the basal cell phenotype found in the growing and healing airway33. We 
repeated a time course evaluation for both TF protein and TF mRNA levels to determine the 
optimal time of exposure to LPS and found TF protein levels to be the highest after 24 hours of 
LPS exposure and TF mRNA signal to be the highest after 3 hours of exposure. NHBE cells were 
exposed to 10 ug/mL E. coli LPS added to 500 uL of cell media for either 3 hours or 24 hours.        
NHBE exposed to LPS demonstrated a nearly 2-fold increase (p < 0.01) in released TF protein 
compared to the control groups (Figure 2a). TF mRNA levels were not affected by LPS exposure 
(Figure 2b). 
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Figure 2: Undifferentiated NHBE releases TF protein when exposed to LPS. 
(A) NHBE exposed to 10 ug/mL LPS for 24 hours released > 50% more TF protein than those 
exposed to vehicle (p < 0.001). Three different cell lines were used to verify this observation 
and data were normalized to reflect change vs. control. (B) TF mRNA did not increase after 
exposure to 10 ug/mL LPS for 3 hours. Results normalized to reflect change vs. control. Results 
are reported as means with error bars indicating standard error.  
A. 
 
B. 
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3.2.3 LPS-induced TF release from NHBE is mediated by MEK/ERK signaling 
  
LPS has been reported to induce TF release from monocytes via MEK/ERK signaling and AP-1 
activation1-4. It also activates IKK signaling pathways which increase NFKB37. To evaluate the 
signaling pathways involved in LPS-induced TF release from NHBE, we exposed cells to a 
MEK/ERK-selective inhibitor (PD98059, 10 + 20uM) and an IKK-selective inhibitor (PS1145, 15 + 
30uM) in the presence of 10 ug/mL LPS or vehicle. Inhibitor concentrations were selected based 
on previously reported experiments36, 38. TF protein levels in cell media were measured by ELISA 
after 24 hours of exposure.  
NHBE treated with PD98059 did not release more TF when exposed to LPS than the control 
group (Figure 3a). Treatment with PS1145 did not prevent LPS-induced increased TF release 
from NHBE (Figure 3b). These results suggest that TLR-4 activation by LPS leads to TF release via 
MEK/ERK signaling and not IKK signaling.   
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Figure 3: LPS-induced TF release from NHBE is mediated by MEK/ERK signaling. 
 
(A) NHBE exposed to 10 ug/mL LPS for 24 hours released more TF than control group (p < 0.05, 
indicated by asterisks); NHBE exposed to 10 ug/mL LPS for 24 hours in the presence of 20 uM 
PD98059, a MEK/ERK inhibitor, did not release more TF than control. (B) The addition of 15 or 
30 uM PS1145 did not alter the release of TF after exposure to 24 hours of ug/mL LPS compated 
to control group (p < 0.05, indicated by asterisks). Results normalized to reflect change vs. 
control and reported as means with error bars indicating standard error. 
 
A. 
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B. 
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3.2.4 NHBE TGF-beta levels increase after LPS exposure 
  
TGF-beta contributes to wound healing and tissue remodeling in airway disease39-42. To 
evaluate the effects of LPS on TGF-beta in NHBE, we exposed cells to 10 ug/mL LPS for time 
points as described above; the largest levels of TGF-beta were found at 24 hours of exposure 
and this duration was used for subsequent experiments. TGF-beta protein levels were then 
evaluated in cell media and lysate by ELISA.  
NHBE exposed to LPS demonstrated a 10-fold increase in TGF-beta protein in cell lysate 
compared to the control group (p < 0.05, Figure 4A). There was no change in TGF-beta protein 
in cell media (Figure 4B). These results indicate that TLR-4 activation increases intracellular TGF-
beta protein as well as released TF protein levels.      
 
3.2.5 TF protein is released from NHBE after exposure to TGF-beta 
  
We then investigated the effect of TGF-beta on TF. We exposed NHBE to several 
concentrations of TGF-beta for 24 hours after which we quantified TF protein levels in cell 
media by ELISA. The cells used in these experiments were grown in submerged conditions.   
NHBE exposed to TGF-beta demonstrated a dose-dependent increase in released TF protein 
compared to the control groups (p < 0.01, Figure 5A). TF mRNA levels were not affected by TGF-
beta exposure (Figure 5B). These results, paired with the demonstration that LPS leads to 
increased intracellular but not released TGF-beta, suggest that LPS-induced TF protein release 
may be mediated by autocrine upregulation of and signaling by TGF-beta.  
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Figure 4: NHBE TGF-beta protein levels increase after exposure to LPS.  
(A) Levels of TGF-beta protein did not increase in cell media after 24 hour exposure to LPS 
(results normalized to reflect change vs. control). (B) Levels of TGF-beta protein in NHBE cell 
lysate increased  after 24 hour exposure to 10 ug/mL LPS (p < 0.05, indicated by asterisk). 
Results are reported as means with error bars indicating standard error. 
A. 
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Figure 5: NHBE exposed to TGF-beta for 24 hours release TF in a concentration-dependent 
manner.  
 
(A) NHBE exposed to 1000 pg/mL, 500 pg/mL, or 250 pg/mL TGF-beta for 24 hours released 
more TF than control group (p < 0.01 indicated by **, p < 0.05 indicated by *). NHBE exposed to 
125 pg/mL TGF-beta did not release more TF than control (A). Results are reported as means 
with error bars indicating standard error. (B) No change in TF mRNA was found after exposure 
to 1000 pg/mL TGF-beta (results normalized to reflect change vs. control).  
 
A. 
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B. 
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3.2.6 NHBE TF release after TGF-beta exposure is mediated by SMAD signaling  
 
TGF-beta activates the TGF-beta receptor complex and initiates SMAD and SMAD-
independent signaling pathways39, 40. To evaluate signaling pathways involved in TGF-beta-
induced TF release from NHBE, we exposed cells to different concentrations of SMAD-selective 
inhibitor (SB431542) in the presence of 10 ug/mL LPS or vehicle as described above; inhibitor 
doses were selected based on previously reported experiments (Figure 6)39. TF protein levels in 
cell media were measured by ELISA after 24 hours of exposure.  
 NHBE treated with 20 uM SB431542 did not release more TF than the control group when 
exposed to LPS (Figure 6). These results suggest that the release of TF after exposure to LPS is 
mediated by SMAD signaling through the TGF-beta receptor complex. This also supports the 
hypothesis that LPS-induced TF protein release is mediated by autocrine TGF-beta signaling.   
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Figure 6: LPS-induced Increased TF release from NHBE is mediated by SMAD signaling. 
 
NHBE exposed to 10 ug/mL LPS or 1000 pg/mL TGF-beta for 24 hours released approximately 
50% more TF compared to control (p < 0.01). NHBE exposed to 10 ug/mL LPS + 100 uM 
SB431542, a SMAD inhibitor, did not release more TF compared to control and released less TF 
than those treated with LPS or TGF-beta (p < 0.01). Lower doses of SB431542 had no effect on 
TF release. Results normalized to reflect change vs. control and reported as means with error 
bars indicating standard error; statistical significance indicated by asterisks. 
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Chapter 4: Effects of TF Inhibition on NHBE Growth 
 
 
4.1 Rationale and Hypothesis: 
 
Having previously demonstrated that NHBE grown under submerged conditions 
constitutively release TF, we decided to evaluate the effect of inhibiting TF in these cells on cell 
growth.  Since our results showed that NHBE release TF after exposure to LPS by a mechanism 
mediated by TGF-beta superfamily signaling, we hypothesized that this was part of a local 
wound healing/repair mechanism. Specifically, we hypothesized that selective inhibition of TF 
via exposure to TFPI would increase the time required for NHBE to reach confluence under 
submerged conditions. 
 
 
4.2 Results – TFPI Decreases NHBE Growth 
 
To evaluate the effects of TFPI on cell growth, we added TFPI to cell media throughout the 
course of submerged cell culture. Several doses of TFPI were used in different groups and 
compared to a vehicle group used as a control.  The cells used in these experiments were grown 
in submerged conditions described above (Image 2a) with media changed every 48 hours. 
Confluence was evaluated via light microscopy prior to each media change. The control group 
reached confluence after six days at which point confluence was measured in each group and 
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recorded.  After the final media change and confluence evaluation, LDH levels in each group 
were measured to rule out cytotoxic effects of TFPI.    
NHBE treated with TFPI grew significantly slower than the control group, reaching less than 
50% confluence by the time the control group was fully confluent (Figure 7a, P < 0.001). This 
phenomenon was dose-dependent. LDH was not different between any of the groups (Figure 
7b, P < 0.001), indicating that the lower numbers of cells was not caused by cytotoxicity. These 
results suggest that TF aids cell growth which is a function closely related to wound repair28, 41, 
42. These results also indicate that inhibition of TF can occur without local cytotoxicity. 
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Figure 7: TFPI slows NHBE growth in a dose-dependent manner. 
 
(A) NHBE exposed to 1000 pg/mL or 500 pg/mL TFPI grew significantly slower that those 
exposed to 250 pg/mL TFPI and the control group (p < 0.05). Images of each exposure group are 
below their respective column in the bar graph. Results are reported as means with error bars 
indicating standard error. (B) LDH was not significantly different between the control or 
treatment groups (p > 0.05). 
 
A. 
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Chapter 5: Discussion 
 
The canonical functions of TF as initiator of coagulation and subsequent clot formation is 
integral to wound healing5, 21, 22. The increased levels of TF found within the inflamed airway 
(including during asthma15, 19, pneumonia16, 17, bronchopulmonary dysplasia18, and acute 
respiratory distress syndrome14, 27) suggest that TF might have other roles as well. The airway 
source of TF, its mechanism for production and release, and the function of TF within airways 
are largely unknown. Non-canonical functions of TF have been reported that further support 
the role of TF in cell growth.  Specifically, TF has been shown to reduce the activation of 
apoptosis pathways and promote metastasis3.   
In vitro dysregulation of TF via selective inhibitors or knock-down models leads to systemic 
hemorrhage; fatal pulmonary hemorrhage occurs in TF knockout mice shortly after birth5, 28, 30. 
TF levels have been shown to be profoundly increased at sites of active wound healing and 
inhibition of TF by administration of TFPI is associated with increased healing/clotting time21, 22. 
This knowledge supports the theory that TF supports wound healing/repair and that TFPI 
inhibits these processes. 
LPS is a well-described initiator of inflammatory responses35-37. LPS binds to TLR-4 and 
activates intracellular signaling pathways, including MEK/ERK37.  We have previously reported 
that 10 ug/mL LPS will activate MEK/ERK without causing cell death and used this model for our 
reported experiments36, 38. These experiments resulted in similar TF release from NHBE as that 
reported after cyclic stress20.   
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In 2009, Brims et al reported that subjects with severe asthma had higher levels of TF in 
their sputum than subjects with moderate asthma or control subjects, even while undergoing 
treatment15. Park et al reported a significant increase in released TF protein from NHBE after 
exposure to cyclic stress levels similar to those reported in the asthma airway20. Since cyclic 
stress can cause epithelial injury, the TF function to create a “patch on a hole” when vascular 
endothelium ruptures could serve similarly within the airways. Also, TGF-beta regulates many 
of the processes surrounding wound healing and is increased in many cell types after exposure 
to LPS39-42. Local increases of TGF-beta in the airways are associated with airway remodeling in 
severe asthma, which is thought to involve a dysregulated and excessive wound healing 
processes39, 40, 42. It is also possible that increases in local TF could contribute to airway 
remodeling; this possibility is supported by our finding that inhibition of TF slows the growth of 
airway cells.    
When interpreted as a whole, our experiments indicate a complex sequential mechanism 
leading to TF release from NHBE after exposure to LPS. Our initial experiment which 
demonstrated the release of TF from NHBE after LPS exposure is only novel due to the cell 
types evaluated. This phenomenon has been observed in cell types typically involved in 
hemostasis including monocytes and vascular endothelium1-4.  Groups have also reported 
findings similar to ours regarding MEK/ERK signal mediation of LPS-induced TF and TGF-beta 
release1-4, 43, 44. The data presented here is novel due to the cell types evaluated, but more 
importantly because it ties together several processes previously thought to be independent of 
one another.  Through selective inhibitors and agonists applied in a stepwise manner, we have 
demonstrated that LPS-induced TLR-4 activation (1) leads to MEK/ERK signaling (2) and 
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subsequent increases in TGF-beta levels (3), SMAD-signaling (4), and TF protein release (5) from 
undifferentiated NHBE cells (Image 6). Since TGF-beta levels were not increased in cell media, it 
is likely that this is an autocrine mechanism and not paracrine. It is possible that this 
mechanism is responsible for LPS-induced TF release from other cells types, although this has 
yet to be investigated.  
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Image 6: Cartoon illustration of proposed autocrine mechanism. 
 
Exposure of NHBE to LPS leads to TLR-4 activated, MEK/ERK-mediated increase in TGF-beta. 
This leads to TGF-beta receptor activation and SMAD-mediated TF release. The curved arc 
represents the cell membrane. 
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TFPI is a strong inhibitor of TF in vitro and in vivo6, 7, 31, 32. It prevents TF from forming clots 
or promoting tissue growth by destabilizing activated TF/FVII complexes or FX and therefore 
preventing the coagulation cascade.  Airway epithelia can produce FVII constitutively that can 
bind with TF45. Along with maintaining hemostasis, these complexes promote cell migration and 
organized tissue formation as seen during cell growth and wound healing46. Our experiments 
evaluating the effects of TF inhibition by TFPI on NHBE cell growth suggest a local repair/wound 
healing function of TF within the airways.   
Unlike the ALI model used by Park et al20, the submerged cell culture conditions we used 
prevent cells from fully differentiating to pseudostratified ciliated columnar epithelia in vivo 
and instead stay in a form that resembles basal cell morphology34, 35. We initially exposed 
differentiated cells grown in ALI to LPS and saw no increase in TF (Figure 1). Since submerged, 
undifferentiated cells are actively growing and dividing, and these process are similar to wound 
healing (a process that begins with basal cells in the epithelium), this could explain why we did 
not observe the release of TF from differentiated NHBE when we exposed them to LPS. Rather, 
differentiated cells may release TF in response to damage33. Of note, the bottom layer of cells 
grown in air-liquid interface differentiate as basal cells; in discussions with Dr. Park, I learned 
that the TF release she reported did not come from pseudostratified ciliated columnar 
epithelium but rather from basal cells in their culture model (J-A Park; April 2017, personal 
communication).  Since cyclic stress is more likely to disrupt the layers of cells than LPS 
exposure, this could further explain why we did not see TF protein released from differentiated 
cells.   
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A confounder in our results is the lack of an observed increase in TF mRNA after exposure to 
LPS.  Park et al noted an increase in both TF mRNA and released TF protein after exposing 
airway cells to cyclic stress. We exposed several different cell lines to LPS at various time 
courses and never found a difference in TF mRNA between control and treatment groups. Park 
et al reported that the TF mRNA increase and protein release was mediated by PKC signaling 
whereas we report that LPS induced TF release is mediated by MEK/ERK signaling. It is possible 
that MEK/ERK signaling leads to increased release of TF protein via exosomes (as reported by 
Park et al) but not an increase in TF mRNA signal.   
These studies had several limitations. Most notably, we did not evaluate the effects of TF on 
wound repair in differentiated airway epithelium nor the mechanism by which TF acts. TF/FVII 
complexes have been shown to activate intracellular signaling of mitogen-activated protein 
kinases, protease-activated receptors, and apoptotic pathways3. We intend to evaluate these 
remaining questions in the future to better characterize the role of TF within the airways and as 
potential therapeutic targets.   
Signaling pathways were evaluated by selective inhibitors as opposed to RNA interference 
or knockout cells. We intend to evaluate phosphorylation of ERK to further support the role of 
this signaling pathway in TF release and decrease any likelihood that our results are related to 
non-specific effects of the MEK/ERK inhibitor.  
We did not design experiments to evaluate specific mechanisms of TFPI delaying NHBE 
growth; rather, these data are descriptive. Further studies to evaluate the effects of TFPI on 
intracellular signaling pathways associated with TF/FVII complex formation and the effect of 
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TFPI on the cell cycle are planned.  It also would be worthwhile to evaluate the effects of other 
reported inhibitors of TF such as AP-147.  
Our data from diverse cell lines using stepwise inhibition and stimulation demonstrate that 
NHBE release TF in response to LPS exposure. This release is mediated by TGF-beta signaling 
and regulated by MEK/ERK and SMAD signaling pathways which may function as an autocrine 
mechanism. Inhibition of TF by TFPI slows airway cell growth, similar to the slowed clotting and 
healing that occurs in other settings when TF is inhibited.  Based upon the results we report, 
inhibitors of TF and the pathways leading to its release during inflammation could be 
therapeutic targets for severe asthma.  
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James HR, Patrie JT, Hunt W, O'Rourke AK, Davis MD, Steinke JW, Lu X, Kennedy J, Heymann 
PW. 
J Allergy Clin Immunol. 2012 Jun;129(6):1499-1505.e5. doi: 10.1016/j.jaci.2012.03.040. 
 
Select Scientific Meeting Abstracts and Presentations 
Poster Presentation: “Normal Human Bronchial Epithelium Release Tissue Factor via ERK1/2 in 
Response to Lipopolysaccharide Stimulation” – 113th Annual Conference of the American 
Thoracic Society, Washington, DC, 05/2017 
 
Lecture/Presentation: “Plastic Bronchitis and Pulmonary Lymphatic Abnormalities: New 
Frontiers in Pulmonary Medicine” – Invited Guest Lecturer, University of Manchester Division of 
Respiratory Medicine, Manchester, England, 04/2016 
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Lecture/Presentation: “Breath Goes In, What Comes Out? An Overview of Exhaled Breath 
Biomarkers” – 59th International Respiratory Conference of the AARC, Tampa, Florida, 11/2015 
 
Lecture/Presentation: “Breath Goes In, What Comes Out? An Overview of Exhaled Breath 
Biomarkers” – 59th International Respiratory Conference of the AARC, Tampa, Florida, 11/2015 
 
Lecture/Presentation: “Assessment and Treatment of the Respiratory Patient” – National Grand 
Rounds, JFK Hospital, Monrovia, Liberia, 10/2015 
 
Lecture/Presentation: “Exhaled Breath Condensate Biomarkers in Critically Ill, Mechanically 
Ventilated Adults” – International Association of Breath Research 10th Anniversary Summit, 
Vienna, Austria, 09/2015 
 
Lecture/Presentation: “Advances in Respiratory Monitoring Have Improved Outcomes – a 
Pro/Con session” – 58th International Respiratory Conference of the AARC, Las Vegas, NV, 
11/2014 
 
Poster Presentation: “Airway Acidity in Critically Ill, Mechanically Ventilated Adults” -8th 
International Conference on Breath Research & Cancer Diagnosis, Torun, Poland, 07/2014 
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Keynote Lecture: “Relationships between exhaled nitric oxide, volumetric capnography and 
pulmonary status in patients with rib fractures” - 8th International Conference on Breath 
Research & Cancer Diagnosis, Torun, Poland, 07/2014 
 
Poster/Presentation: “Methods for Evaluating the Pulmonary Effects of Swimming in 
Chlorinated Water” - 58th International Respiratory Conference of the AARC/Journal of 
Respiratory Care, 11/2012 
 
Grants/Funding 
Mallinckrodt Pharmaceuticals, Investigator Initiated Study 
Comparing the inflammatory effects of nitric oxide and two formulations of epoprostenol on 
human bronchial epithelium. 
Role: Principal Investigator 
Amount: $100,000 
Award Date: 07/2016 
 
American Respiratory Care Foundation Frances B. Parker Grant Fund 
The Role of Tissue Factor in Inflammatory Airway Disease. 
Role: Principal Investigator 
Amount: $20,000 
Award Date: 01/2016 
 
